Clinical trials: Lactic Acid/Metabolism
- Condition Lactic Acid/Metabolism
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Shock, Hemorrhagic, Shock, Traumatic
Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients
MP4OX is a novel oxygen therapeutic agent being developed as an ischemic rescue therapy to enhance perfusion and oxygenation of tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid.
- Conditions
- Shock, Hemorrhagic, Shock, Traumatic, Acidosis, Lactic
- Trial name
- NCT01262196
- Testing
- MP4OX, Saline
- Where
- 40 sites in Australia, Austria and 12 more
- Volunteers
- 348 people
- Sponsor
- Sangart
Acidosis
Safety of D-lactate Producing Probiotics
In this study the investigators want to test the safety of D-lactate producing probiotics in babies from birth to 1 month of age.
- Trial name
- NCT01119170
- Testing
- Starter formula, starter formula with D-lactate producing probiotics
- Where
- Greece
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203.
- Trial name
- NCT06961344
- Testing
- zagociguat 15mg
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 37 people
- Sponsor
- Tisento Therapeutics
Sports Injury
Clinical Trial for Vespa Amino Acid Mixture (VAAM®)
ATP is generated mainly through anaerobic metabolism during strenuous exercise, which is then followed by the generation of lactic acid.
- Trial name
- NCT03121040
- Testing
- Vespa amino acid mixture
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shanghai Meiji Health Science and Technology Co., Ltd.
Mitochondrial Diseases
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study…
- Trial name
- NCT02473445
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen